ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1715-1722

  Yuan, Shao ^a   Lei, Shi ^a   Wu, Shengli ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

A disintegrin and metalloproteinase; Hepatocellular carcinoma; HepG2 cells; SiRNA

Indexed keywords

ADAM10 ENDOPEPTIDASE; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADAM PROTEINS; ADULT; AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84882715056     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2650     Document Type: Article

References (36)

1. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
2. Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
3. Wang N, Feng Y, Lau EP, et al: F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther 9: 354-364, 2010.
4. Kanai T, Hirohashi S, Upton MP, et al: Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 60: 810-819, 1987.
5. Saftig P and Reiss K: The 'A Disintegrin And Metalloproteases' ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 90: 527-535, 2011.
6. Crawford HC, Dempsey PJ, Brown G, Adam L and Moss ML: ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 15: 2288-2299, 2009.
7. Postina R, Schroeder A, Dewachter I, et al: A disintegrin- metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464, 2004.
8. Naus S, Blanchet MR, Gossens K, Zaph C, Bartsch JW, McNagny KM and Ziltener HJ: The metalloprotease-disintegrin ADAM8 is essential for the development of experimental asthma. Am J Respir Crit Care Med 181: 1318-1328, 2010.
9. Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8: 929-941, 2008.
10. Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets 8: 720-732, 2008.
11. Becherer JD and Blobel CP: Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 54: 101-123, 2003.
12. Huang J, Bridges LC and White JM: Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell 16: 4982-4991, 2005.
13. Doberstein K, Pfeilschifter J and Gutwein P: The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma. Carcinogenesis 32: 1713-1723, 2011.
14. Gaida MM, Haag N, Günther F, et al: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 26: 281-288, 2010.
15. Guo J, He L, Yuan P, et al: ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. Oncol Rep 28: 1709-1718, 2012.
16. Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and Tao HQ: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J Surg Oncol 103: 116-123, 2011.
17. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 245: 33-43, 2007.
18. Lee SB, Schramme A, Doberstein K, et al: ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130: 763-773, 2010.
19. Turner SL, Blair-Zajdel ME and Bunning RA: ADAMs and ADAMTSs in cancer. Br J Biomed Sci 66: 117-128, 2009.
20. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W and Choti MA: Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 245: 435-442, 2007.
21. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928, 1985.
22. Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H and Zhang Z: Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer 120: 1909-1913, 2007.
23. Xu Q, Liu X, Chen W and Zhang Z: Inhibiting adenoid cystic carcinoma cell growth and metastasis by blocking the expression of ADAM 10 using RNA interference. J Transl Med 8: 136, 2010.
24. Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200, 2005.
25. Zhu W, Owusu L, Zang S, Zhang Y, Xin Y and Yan C: GRP78 and GAL3, differentially regulated by lymph node homogenates, as potential biomarkers for lymph node metastasis in mouse hepatocellular carcinoma cells. Oncol Lett 4: 1374-1378, 2012.
26. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642, 2005.
27. Arima T, Enokida H, Kubo H, et al: Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci 98: 1720-1726, 2007.
28. Jorissen E, Prox J, Bernreuther C, et al: The disintegrin/ metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30: 4833-4844, 2010.
29. Jacobsen KT, Adlerz L, Multhaup G and Iverfeldt K: Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-β precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J Biol Chem 285: 10223-10231, 2010.
30. Venkataramani V, Rossner C, Iffland L, et al: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 285: 10678-10689, 2010.
31. Fan X, Liu Y, Jiang J, et al: miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin 42: 318-324, 2010.
32. Pan Y, Han C, Wang C, et al: ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1. J Mol Endocrinol 49: 21-33, 2012.
33. Anderegg U, Eichenberg T, Parthaune T, et al: ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 129: 1471-1482, 2009.
34. DeCicco-Skinner KL, Nolan SJ, Deshpande MM, Trovato EL, Dempsey TA and Wiest JS: Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice. PLoS One 8: e56212, 2013.
35. Massi D, Tarantini F, Franchi A, et al: Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 19: 246-254, 2006.
36. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K and Altevogt P: Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 275: 15490-15497, 2000.